Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery
暂无分享,去创建一个
Robert Langer | Gaurav Sahay | Hao Yin | Daniel G Anderson | Daniel G. Anderson | R. Langer | C. Alabi | G. Sahay | Hao Yin | Kevin T. Love | K. Luly | Kevin T Love | Christopher A Alabi | Kathryn M Luly | Kathryn M. Luly
[1] S. Milstein,et al. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation , 2013, Cancer Immunology, Immunotherapy.
[2] C. Alabi,et al. Attacking the genome: emerging siRNA nanocarriers from concept to clinic. , 2012, Current opinion in pharmacology.
[3] Daniel G. Anderson,et al. FRET-labeled siRNA probes for tracking assembly and disassembly of siRNA nanocomplexes. , 2012, ACS nano.
[4] Juliane Nguyen,et al. Nucleic acid delivery: the missing pieces of the puzzle? , 2012, Accounts of chemical research.
[5] Y. J. Kwon. Before and after endosomal escape: roles of stimuli-converting siRNA/polymer interactions in determining gene silencing efficiency. , 2012, Accounts of chemical research.
[6] Shigeo Matsuda,et al. Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo** , 2012, Angewandte Chemie.
[7] Farnaz Niroui,et al. In vitro-in vivo translation of lipid nanoparticles for hepatocellular siRNA delivery. , 2012, ACS nano.
[8] M. B. Banaszak Holl,et al. Efficient in vitro siRNA delivery and intramuscular gene silencing using PEG-modified PAMAM dendrimers. , 2012, Molecular pharmaceutics.
[9] J. Ritter,et al. Abstract 67: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Results for ALN-PCS, a Novel RNAi Therapeutic for the Treatment of Hypercholesterolemia , 2012, Arteriosclerosis, Thrombosis, and Vascular Biology.
[10] Daniel G. Anderson,et al. Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells , 2012, Molecular therapy. Nucleic acids.
[11] Daniel G. Anderson,et al. Therapeutic siRNA silencing in inflammatory monocytes , 2011, Nature Biotechnology.
[12] Vineet Kumar,et al. Nanocarriers: a tool to overcome biological barriers in siRNA delivery , 2011, Expert opinion on biological therapy.
[13] D. Levorse,et al. Interaction of cholesterol-conjugated ionizable amino lipids with biomembranes: lipid polymorphism, structure-activity relationship, and implications for siRNA delivery. , 2011, Langmuir : the ACS journal of surfaces and colloids.
[14] Gert Storm,et al. Endosomal escape pathways for delivery of biologicals. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[15] D. Levorse,et al. Ionization behavior of amino lipids for siRNA delivery: determination of ionization constants, SAR, and the impact of lipid pKa on cationic lipid-biomembrane interactions. , 2011, Langmuir : the ACS journal of surfaces and colloids.
[16] K. G. Rajeev,et al. Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[17] J. Au,et al. Delivery of siRNA Therapeutics: Barriers and Carriers , 2010, The AAPS Journal.
[18] D. Dykxhoorn,et al. Breaking down the barriers: siRNA delivery and endosome escape , 2010, Journal of Cell Science.
[19] K. G. Rajeev,et al. Rational design of cationic lipids for siRNA delivery , 2010, Nature Biotechnology.
[20] Kathryn A. Whitehead,et al. Lipid-like materials for low-dose, in vivo gene silencing , 2010, Proceedings of the National Academy of Sciences.
[21] E. Wagner,et al. Hydrophobically modified oligoethylenimines as highly efficient transfection agents for siRNA delivery. , 2009, Bioconjugate chemistry.
[22] T. Kissel,et al. Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[23] Michael S. Goldberg,et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[24] Mark E. Davis. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. , 2009, Molecular pharmaceutics.
[25] Daniel G. Anderson,et al. Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.
[26] Stephanie E. A. Gratton,et al. The effect of particle design on cellular internalization pathways , 2008, Proceedings of the National Academy of Sciences.
[27] Robert Langer,et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.
[28] K. Braeckmans,et al. A fast and sensitive method for measuring the integrity of siRNA-carrier complexes in full human serum. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[29] G. Sczakiel,et al. Cellular uptake and intracellular release are major obstacles to the therapeutic application of siRNA: novel options by phosphorothioate-stimulated delivery , 2007, Expert opinion on biological therapy.
[30] Darren H. Wakefield,et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes , 2007, Proceedings of the National Academy of Sciences.
[31] A. Klippel,et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium , 2006, Gene Therapy.
[32] Mark E. Davis,et al. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging , 2006, Nucleic acids research.
[33] J. Heyes,et al. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[34] A. Urtti,et al. Cell‐surface glycosaminoglycans inhibit cation‐mediated gene transfer , 2004, The journal of gene medicine.
[35] N. Demaurex. pH Homeostasis of cellular organelles. , 2002, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.
[36] D. Lauffenburger,et al. Quantitative analysis of synthetic gene delivery vector design properties. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[37] A. Urtti,et al. Extracellular Glycosaminoglycans Modify Cellular Trafficking of Lipoplexes and Polyplexes* , 2001, The Journal of Biological Chemistry.
[38] P. Cullis,et al. Modulation of membrane fusion by asymmetric transbilayer distributions of amino lipids. , 1994, Biochemistry.
[39] W. H. Evans,et al. Phospholipid, cholesterol, polypeptide and glycoprotein composition of hepatic endosome subfractions. , 1985, The Biochemical journal.
[40] N. Dhalla,et al. Excitation-contraction coupling in heart. 3. Evidence against the involvement of adenosine cyclic 3',5'-monophosphate in calcium transport by sarcotubular vesicles of canine myocardium. , 1970, Molecular pharmacology.
[41] N. Demaurex. Homeostasis of cellular organelles , 2022 .